Merck & Co., Inc., known as MSD Animal Health outside the United States and Canada, has announced that its new product, BRAVECTO® QUANTUM, has received approval from the U.S. Food and Drug Administration (FDA). This once-yearly injectable treatment provides dogs with year-round protection against fleas and ticks. The product is expected to be available in veterinary clinics and hospitals across the United States by August 2025. BRAVECTO QUANTUM, which utilizes a unique composition of fluralaner, has already been approved in more than 50 countries, including Australia, New Zealand, and the European Union. The product has been recognized with awards for its innovative approach to pet care.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。